Immunocore Holdings plc filings document the formal disclosures of an England and Wales biotechnology company with American Depositary Shares, each representing one ordinary share, listed on Nasdaq. Recent 8-K reports furnish quarterly and annual financial results, preliminary liquidity information and corporate updates through press-release exhibits.
The filing record also includes proxy materials for the annual general meeting, covering shareholder voting procedures for ordinary shares and ADSs, and Item 5.02 disclosure on R&D leadership changes and related organizational structure. These documents describe the company’s ADS and ordinary-share capital framework, governance processes, executive matters and material-event reporting tied to its commercial-stage ImmTAX platform business.
Immunocore Holdings plc (IMCR) is the subject of an exit amendment filed jointly by Bellevue Group AG and its wholly owned subsidiary, Bellevue Asset Management AG. The joint report lists 2,264,321 ordinary shares beneficially owned, with shared voting and dispositive power over that amount; the reported stake is 4.4%.
For Immunocore Holdings plc (IMCR), Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen each reported shared beneficial ownership of 2,720,043 ordinary shares and shared voting and dispositive power over that amount, equal to 5.2% of the class, as of November 6, 2026.
The reported amount includes 501,604 ordinary shares represented by ADSs issuable upon conversion of convertible notes. Point72 Asset Management maintains investment and voting power over securities held by Point72 Associates, LLC, which has the right to receive or direct dividends or sale proceeds from more than 5% of the outstanding ordinary shares. The reporting persons state they directly own no ordinary shares and that the report is not an admission of beneficial ownership under the Act. Jason M. Colombo signed as an authorized person.
Immunocore Holdings plc (IMCR) reported $324.8 million in net KIMMTRAK therapy revenue for the nine months ended September 30, 2026, up 9.9% year over year; third-quarter revenue was $102.2 million, down 1.4%. Nine-month net loss narrowed to $2.1 million from $5.5 million, while third-quarter net loss was $14.2 million versus $177,000 a year earlier. Operating cash flow for the nine months was $22.2 million, compared with $21.9 million.
At September 30, 2026, cash and cash equivalents were $512.2 million and marketable securities were $389.1 million. Immunocore expects those balances, together with anticipated KIMMTRAK revenue, to fund operating expenses and capital expenditures for at least twelve months from the date of this Quarterly Report. Its Phase 3 TEBE-AM trial reached target enrollment of 540 patients; topline overall survival data are expected in the second quarter of 2027. The Phase 1 trial of IMC-S118AI also dosed its first person with type 1 diabetes in October 2026.
Immunocore Holdings plc (IMCR) reported Q3 2026 KIMMTRAK net sales of $102.2 million, versus $103.7 million a year earlier. After adjusting for U.S. wholesaler stocking in Q2 and one additional U.S. sales week in Q3 2025, the company said underlying quarterly growth was approximately 10%. Nine-month sales were $324.8 million, up 10% year over year from $295.5 million. Q3 net loss was $14.2 million versus $0.2 million; nine-month net loss was $2.1 million versus $5.5 million.
Cash, cash equivalents and marketable securities were $901.3 million as of September 30, 2026, versus $864.2 million as of December 31, 2025. Immunocore expects to pay approximately $120 million in sales-related rebate accruals in Q4 2026. Phase 3 TEBE-AM completed enrollment of 540 patients, with topline overall survival data expected in Q2 2027. The first person with type 1 diabetes was dosed in the Phase 1 IMC-S118AI trial.
In reported Phase 1/2 data for 17 evaluable first-line patients, KIMMTRAK plus brenetafusp had a 29% overall response rate, 24.1-month median duration of response and 8.1-month median progression-free survival; median overall survival was not reached with 29 months of follow-up. Immunocore plans to start the randomized Phase 2/3 DUET-UVEAL trial.
Immunocore Holdings plc (IMCR) is covered by an amended beneficial-ownership report from FMR LLC and Abigail P. Johnson. FMR reported beneficial ownership of 1,736,979 common shares, or 3.6% of the class. It reported sole voting power over 1,732,649 shares and sole dispositive power over 1,736,979 shares, with no shared voting or dispositive power.
Abigail P. Johnson's cover-page figures report no voting power and sole dispositive power over 1,736,979 shares. The report states that other persons may have rights to dividends or sale proceeds, but no other person's interest exceeds 5% of the class.
Immunocore Holdings plc (IMCR) reports that it has achieved target enrollment of 540 patients in its global, randomized, registrational Phase 3 TEBE-AM trial of KIMMTRAK (tebentafusp) as monotherapy and in combination with pembrolizumab versus Investigator’s Choice in HLA-A*02:01-positive advanced melanoma after prior therapy. The primary endpoint is overall survival, and the company expects to share topline overall survival data as early as the end of 2026. KIMMTRAK, developed from Immunocore’s ImmTAC TCR bispecific platform, is already approved for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in multiple major markets.
Immunocore Holdings plc has a significant institutional holder, Vestal Point Capital, LP, which, together with Ryan Wilder, reports beneficial ownership of 1,800,000 American Depository Shares (ADS). These ADS each represent one ordinary share of Immunocore.
This position represents 3.5% of Immunocore’s outstanding shares, based on 50,865,574 shares, including ADS, outstanding as of April 30, 2026, as reported by the company. Vestal Point Capital and Ryan Wilder report shared voting and shared dispositive power over all 1,800,000 ADS, with no sole voting or dispositive power. The filing also notes that the investors now hold 5% or less of the class, and includes standard language that the reporting persons do not admit to being beneficial owners for all legal purposes.
Immunocore Holdings plc is reported to have a significant shareholder group led by Wellington Management Group LLP and related entities. They collectively report beneficial ownership of 5,959,773 shares of Immunocore common stock, representing 11.57% of the class as of June 30, 2026. The group reports no sole voting or dispositive power, with all authority held on a shared basis across the Wellington entities. The securities are owned of record by clients of Wellington’s investment advisers, who have the economic rights to dividends and sale proceeds, including Vanguard Health Care Fund, which holds more than five percent of the class through these arrangements.
FMR LLC and Abigail P. Johnson report their beneficial ownership of Immunocore Holdings plc common stock on an amended Schedule 13G. FMR LLC reports beneficial ownership of 4,307,246 shares of common stock, representing 8.8% of the class. These shares are held with sole dispositive power and no shared voting or dispositive power.
Abigail P. Johnson is reported as having sole dispositive power over the same 4,307,246 shares, also representing 8.8% of the outstanding common stock, with no voting or shared dispositive power. One or more other persons have rights to receive dividends or sale proceeds from these securities, but no such person holds more than five percent of the class.
Immunocore Holdings plc delivered solid top-line growth driven by KIMMTRAK. Net revenue from sale of therapies reached $115.9 million in the quarter ended June 30, 2026, up 18.3% year over year, and $222.6 million for the first half, a 16.0% increase.
The company generated first-half net income of $12.2 million versus a loss a year earlier, though it recorded a modest $0.8 million quarterly net loss as investment remained high. R&D expenses were $73.9 million and SG&A $43.9 million in the quarter; R&D for the half-year totaled $135.1 million, reflecting multiple Phase 3 and early-stage programs.
Liquidity is strong with $484.9 million in cash and cash equivalents and $395.3 million in marketable securities as of June 30, 2026, alongside $402.5 million of 2.50% convertible senior notes due 2030. Management highlights progress in late-stage tebentafusp and PRAME-targeted brenetafusp trials, as well as HIV candidate IMC‑M113V and autoimmune candidate IMC‑S118AI.